Perspective Therapeutics (NYSE:CATX) Upgraded by Lifesci Capital to Strong-Buy Rating

Perspective Therapeutics (NYSE:CATX) was upgraded by stock analysts at Lifesci Capital to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other brokerages have also weighed in on CATX. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday, January 24th. Oppenheimer lowered their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.13.

Perspective Therapeutics Stock Performance

CATX opened at $2.61 on Thursday. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05. The stock’s 50 day moving average price is $3.21 and its 200 day moving average price is $7.76.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CATX. US Bancorp DE lifted its holdings in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth approximately $33,000. Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth approximately $137,000. Aigen Investment Management LP purchased a new position in Perspective Therapeutics during the fourth quarter valued at approximately $34,000. Finally, National Bank of Canada FI increased its stake in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.